<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084222</url>
  </required_header>
  <id_info>
    <org_study_id>0010032</org_study_id>
    <nct_id>NCT05084222</nct_id>
  </id_info>
  <brief_title>Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing</brief_title>
  <acronym>EASYRELIEF</acronym>
  <official_title>Use of Buventol Easyhaler and Bufomix Easyhaler as Relievers in Methacholine Challenge Testing and Inspiratory Flow Profiles During Induced Bronchoconstriction in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares Buventol® Easyhaler® and Bufomix® Easyhaler® to the current standard&#xD;
      treatment during methacholine challenge test. The trial will also provide inspiratory flow&#xD;
      profile data for Easyhaler inhaler.&#xD;
&#xD;
      This trial is designed to provide a further evidence for the use of Easyhaler in diagnostic&#xD;
      bronchial challenge tests and on the use of Easyhaler inhaler during obstructive event.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>10 minutes</time_frame>
    <description>Mean change in FEV1 from post-diluent to FEV1 after the first dose of reliever.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who recover from bronchoconstriction after first dose</measure>
    <time_frame>10 minutes</time_frame>
    <description>Proportion of the subjects who recover to FEV1 &gt; -10% compared to post-diluent FEV1 after first dose of reliever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in one second (FEV1)</measure>
    <time_frame>10 minutes</time_frame>
    <description>Relative recovery of FEV1 after the study treatment dosing when compared to post-diluent FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who recover from bronchoconstriction after second dose</measure>
    <time_frame>20 minutes</time_frame>
    <description>Proportions of subjects reaching FEV1 &gt; -10% of post-diluent value after second dose of reliever.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of patients needing medical attention</measure>
    <time_frame>After study treatment administration until study completion (an average of 2.5 hours)</time_frame>
    <description>Proportion of subjects needing medical attention after study treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Inhalation profile via Easyhaler</measure>
    <time_frame>Before methacholine challenge and 10 minutes after the subject experiences FEV1 drop ≥ 20% compared to post-diluent spirometry</time_frame>
    <description>Time-inspiratory flow -curve via Easyhaler measured with spirometer.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Buventol® Easyhaler® 200 µg/inhalation dmDPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 μg of salbutamol from Buventol Easyhaler is administered as two inhalations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>320 μg of budesonide and 9 μg of formoterol are administered from Bufomix Easyhaler as two inhalations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventoline® Evohaler® 100 µg/inhalation pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 μg of salbutamol from Ventoline Evohaler is administered via Volumatic spacer as four inhalations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buventol® Easyhaler® 200 µg/inhalation dmDPI</intervention_name>
    <description>Two doses will be administered</description>
    <arm_group_label>Buventol® Easyhaler® 200 µg/inhalation dmDPI</arm_group_label>
    <other_name>Salbutamol 200 µg/dose dmDPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI</intervention_name>
    <description>Two doses will be administered</description>
    <arm_group_label>Bufomix® Easyhaler® 160/4.5 µg/inhalation dmDPI</arm_group_label>
    <other_name>Budesonide/formoterol 160/4.5 µg/inhalation dmDPI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ventoline® Evohaler® 100 µg/inhalation pMDI</intervention_name>
    <description>Four doses will be administered via Volumatic spacer</description>
    <arm_group_label>Ventoline® Evohaler® 100 µg/inhalation pMDI</arm_group_label>
    <other_name>Salbutamol 100 µg/dose MDI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent (IC) obtained.&#xD;
&#xD;
          2. Finnish speaking adult (≥ 18 years old) subject indicated for methacholine challenge&#xD;
             test.&#xD;
&#xD;
          3. The subject experiences FEV1 drop ≥ 20% compared to post-diluent spirometry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects not eligible for methacholine challenge test for example for any of the&#xD;
             following reasons:&#xD;
&#xD;
               -  Any respiratory infection within 2 weeks, or severe respiratory infection within&#xD;
                  4 weeks before the study visit&#xD;
&#xD;
               -  FEV1 &lt; 60% of predicted or &lt; 1.0 l&#xD;
&#xD;
               -  Inability to perform acceptable and repeatable spirometry manoeuvres throughout&#xD;
                  the test procedure&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Acute chest pain or unstable angina pectoris&#xD;
&#xD;
               -  Significant cardiac arrhythmias&#xD;
&#xD;
               -  Pneumothorax or recent bronchoscopy&#xD;
&#xD;
               -  Myocardial infarction or stroke in last 3 months&#xD;
&#xD;
               -  Known aortic aneurysm&#xD;
&#xD;
               -  Recent eye surgery or intracranial pressure elevation risk&#xD;
&#xD;
               -  Cholinesterase inhibitor medication&#xD;
&#xD;
               -  Pregnant or lactating females&#xD;
&#xD;
          2. Subjects who have used the following treatments before the study visit:&#xD;
&#xD;
               -  Short-acting β-agonists within 12 h&#xD;
&#xD;
               -  Long-acting β-agonists within 36 h&#xD;
&#xD;
               -  Ultra-long-acting β-agonists within 48 h&#xD;
&#xD;
               -  Long-acting anti-muscarinic agents within 168 h&#xD;
&#xD;
               -  Short-acting anticholinergics within 12 h&#xD;
&#xD;
               -  Oral theophylline within 24 h&#xD;
&#xD;
               -  Inhaled corticosteroids, leukotriene receptor antagonists and chromones within 4&#xD;
                  weeks&#xD;
&#xD;
          3. Known hypersensitivity to the active substance(s) or the excipients of the study&#xD;
             treatments (for example severe milk allergy, lactose contains small amounts of milk&#xD;
             protein).&#xD;
&#xD;
          4. Administration of another investigational medicinal product within 30 days before the&#xD;
             study visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iissa Kivistö</last_name>
    <role>Study Director</role>
    <affiliation>Orion Pharma, Espoo, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lauri Lehtimäki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital, Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iissa Kivistö</last_name>
    <phone>+358509665606</phone>
    <email>iissa.kivisto@orionpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Iissa Kivistö</last_name>
      <phone>+358509665606</phone>
      <email>iissa.kivisto@orionpharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

